Revive Therapeutics remains one of the most undervalued companies trading on the OTC Markets. We first covered Revive in September when shares were trading at $.20 a share. The stock has slowly dropped since then. We said in September that RVVTF was a cheap COVID-19 play, which you can read here. At current levels, Revive Therapeutics is not just cheap, it’s an absolute bargain.
In this article, we are going to take a closer look at its psychedelics program. Our last article focused more in-depth on its COVID-19 treatment program, this article will focus more on the magic mushroom side of things. We at Insider Financial are bullish on the psychedelics industry and our subscribers caught the recent move in MMEDF, which you can read here. We believe Revive Therapeutics is next to make a similar move.
First up, here’s a little background info for those not familiar with the company. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations.
Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.
Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
Psilocybin Oral Thin-film Product
Under its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, Revive Therapeutics is developing its tannin-chitosan composite of orally dissolvable thin films that offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity.
Revive Therapeutics has received its final set of prototypes and is preparing to scale for manufacturing for future clinical studies involving psilocybin and other psychedelic-derived medicines.
There are a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients to administer without the need of water, chewing, or swallowing, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders including the flexibility to create accurate dosing and tasteful options.
Revive Therapeutics delivery technology is a natural, non-toxic, biodegradable, and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant, and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties.
The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.
Psilocybin Clinical Study
Revive Therapeutics recently announced that it has entered into a Clinical Trial Agreement with the Board of Regents of the University of Wisconsin System to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.”
The Phase I study Principal Investigator is Dr. Christopher R. Nicholas, Ph.D., Assistant Professor of Program for Research Outreach Therapeutics and Education in the Addictions in the Department of Family Medicine and Community Health at University of Wisconsin School of Medicine and Public Health.
The clinical study will be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health, and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin.
Revive Therapeutics will have exclusive access to key intellectual property from this study.
Revive Therapeutics Supply Agreement With Havn Life Sciences
Revive Therapeutics just signed a supply agreement with Havn Life Sciences Inc. (CSE:HAVN) to source naturally-derived psychedelic compounds, such as psilocybin, for use in future investigational new drug (IND) enabling studies and clinical trials under FDA guidelines. CEO Michael Frank said:
“We are excited about our strategic partnership with Havn Life as one of our suppliers of psychoactive compounds that we intend to develop and commercialize using our established tannin-chitosan based proprietary oral-thin film delivery system, for the pharmaceutical and wellness markets. We are developing unique products with both synthetic and naturally-derived psilocybin and building relationships with companies and institutions that support our objectives in the psychedelic space including our established relationship with the University of Wisconsin-Madison in the research and clinical development of our novel Psilocybin oral-thin film product and the Phase 1 clinical study using psilocybin in the treatment of methamphetamine use disorder.”
Havn Life Sciences is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds.
Revive Therapeutics Bottom Line
Currently trading with a market cap of $34 million, Revive Therapeutics is an exciting story among small caps. Its psychedelics business is like the icing on the cake. It’s an added bonus, but the big potential still lies with its Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. Revive Therapeutics has committed to ten clinical sites across Florida, Texas, Nevada, Arizona, and California. It is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020.
As we said last time, we know of no other biotech that has advanced this far with the FDA and trades at such a low valuation. If RVVTF was listed on the Big Board, it would easily have a multi-billion-dollar market cap.
We see two possible scenarios playing out. One is RVVTF signing a joint venture with Big Pharma to advance its Phase trial. Pfizer is one name that we have been hearing rumors about.
The second is the FDA meets next month to discuss all COVID-19 phase 3 trials. RVVTF will be on that list. Could RVVTF also make the list for Operation Warp Speed Funding? The company certainly qualifies.
Smart investors shouldn’t wait around to jump on the RVVTF train. The recent selloff is a gift for all the dip buyers. Revive Therapeutics is perhaps the best risk/reward setup we have seen all year.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK TIP, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in OTCMKTS:RVVTF or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.